BioSilicon evaluated for delivery systems
PsiMedica, the UK operating subsidiary of pSivida, has entered into an agreement with an unnamed top five global pharmaceutical company to evaluate its proprietary BioSilicon technology for certain drug delivery applications. The agreement covers the evaluation of BioSilicon for the controlled release of a number of selected compounds from injectable depot formulations intended for subcutaneous or intramuscular administration. The pharmaceutical company will fund the direct costs of the programme.
pSivida is currently developing BioSilicon as a novel, biocompatible and biodegradable material, which has many potential applications. The staged evaluation programme for the selected compounds will be conducted by pSiMedica in consultation with the pharmaceutical company, with the potential to extend the programme to additional compounds and endpoints.
pSivida's managing director Gavin Rezos said: 'We believe this will mark the first of a number of such programmes. In 2005 we expect to be able to announce the signing of similar evaluation agreements as well as licensing agreements with other pharmaceutical, biotechnology and device companies.'